Rhythm Pharmaceuticals (RYTM) was raised to a "buy" recommendation by an influential sell-side firm Monday. Shares of this commercial-stage biopharmaceutical company have soared sharply in recent weeks so we want to see how we should proceed.
More from Stocks
Let's review three high-yield business development companies.
Here are six ways to handle the two biggest risks.
The hurt Fed Chair Jerome Powell has been talking about so much lately is no longer an abstract concept on Wall Street. But with the horrible action comes opportunities.
Traders are are trying to find bottoms on an ugly day in the markets